An increased risk of venous thromboembolism (VTE) with COVID-19 infection has been well
documented, particularly in critically ill-hospitalized patients. The presence of cancer, in …

2627 Background: There are increasing reports of thromboembolic complications in patients
with COVID-19 infection. According to a meta-analysis of 28,173 patients, the prevalence of …

e18839 Background: Cancer, as well as immunosuppression from chemotherapy,
aggravates thromboembolism risk. The risk is likely amplified in an additive fashion with …

Background: Increased rates of thromboembolism (TE) have been reported in patients with
COVID-19, even without prior predisposition to thrombosis. Cancer patients are already …

Introduction: Hospitalized patients with COVID-19 may have increased risk of venous
thromboembolism (VTE) and pulmonary embolism (PE). Cancer and anti-cancer therapies …

Introduction: Cancer is a leading cause of morbidity and mortality in the United States, and
cancer patients infected with COVID-19 are at increased risk of death. Given that cancer and …

e24066 Background: COVID-19 is associated with an increased incidence of venous
thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary …

e18823 Background: Cancer patients are at a higher risk of venous thromboembolism and
fatal pulmonary embolism due to inflammatory cytokines, reduced coagulation inhibitors …

Background COVID-19 is associated with increased risk of thromboembolic events, through
endothelial damage, severe hypoxia, and cytokine storm, leading to activation of …

Background An increased risk of thromboembolic events (TE) is associated with COVID-19
infection. However, information available about thrombosis risk in COVID-19 cancer patients …